title: Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
abstract: Elevation of the interstitial fluid pressure (IFP) of carcinoma is an obstacle in treatment of tumors by chemotherapy and correlates with poor drug uptake. Previous studies have shown that treatment with inhibitors of platelet-derived growth factor (PDGF) or vascular endothelial growth factor (VEGF) signaling lowers the IFP of tumors and improve chemotherapy. In this study, we investigated whether the combination of PDGFR and VEGFR inhibitors could further reduce the IFP of KAT-4 human carcinoma tumors. The tumor IFP was measured using the wick-in-needle technique. The combination of STI571 and PTK/ZK gave an additive effect on the lowering of the IFP of KAT-4 tumors, but the timing of the treatment was crucial. The lowering of IFP following combination therapy was accompanied by vascular remodeling and decreased vascular leakiness. The effects of the inhibitors on the therapeutic efficiency of Taxol were investigated. Whereas the anti-PDGF and anti-VEGF treatment did not significantly inhibit tumor growth, the inhibitors enhanced the effect of chemotherapy. Despite having an additive effect in decreasing tumor IFP, the combination therapy did not further enhance the effect of chemotherapy. Simultaneous targeting of VEGFR and PDGFR kinase activity may be a useful strategy to decrease tumor IFP, but the timing of the inhibitors should be carefully determined.
authors.affiliation: Biomedical Center, Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden. Agnieszka.Klosowska-Wardega@LICR.uu.se
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Kłosowska-Wardega
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hasumi
authors.forename: Mikhail
authors.initials: M
authors.lastname: Burmakin
authors.forename: Aive
authors.initials: A
authors.lastname: Ahgren
authors.forename: Linda
authors.initials: L
authors.lastname: Stuhr
authors.forename: Ingrid
authors.initials: I
authors.lastname: Moen
authors.forename: Rolf K
authors.initials: RK
authors.lastname: Reed
authors.forename: Kristofer
authors.initials: K
authors.lastname: Rubin
authors.forename: Carina
authors.initials: C
authors.lastname: Hellberg
authors.forename: Carl-Henrik
authors.initials: CH
authors.lastname: Heldin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001810:Blood Volume / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D045604:Extracellular Fluid / Q000187:drug effects*; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D020286:Pericytes / Q000187:drug effects / Q000473:pathology; D011312:Pressure; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D017479:Receptors, Platelet-Derived Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor